{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:12:10Z","timestamp":1786990330841,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.humpath.2018.06.024","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T17:57:40Z","timestamp":1530035860000},"page":"20-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution\u2019s high-risk population"],"prefix":"10.1016","volume":"82","author":[{"given":"Alice E.","family":"Meiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Modesitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari L.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.06.024_bb0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.breast.2016.05.006","article-title":"Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management","volume":"28","author":"Kleibl","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.humpath.2018.06.024_bb0010","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2018.06.024_bb0015","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","article-title":"Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort","volume":"133","author":"Masciari","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2018.06.024_bb0020","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4161\/epi.6.5.15667","article-title":"CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal\/triple-negative breast cancer","volume":"6","author":"Stefansson","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.humpath.2018.06.024_bb0025","doi-asserted-by":"crossref","first-page":"R465","DOI":"10.1186\/bcr1025","article-title":"Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families","volume":"7","author":"Eerola","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2018.06.024_bb0030","first-page":"3606","article-title":"Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers","volume":"9","author":"Palacios","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.06.024_bb0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-012-2375-z","article-title":"Prevalence of germline TP53 mutations in HER2+ breast cancer patients","volume":"139","author":"Rath","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2018.06.024_bb0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/jmg.2010.079814","article-title":"Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers","volume":"48","author":"Schrader","year":"2011","journal-title":"J Med Genet"},{"key":"10.1016\/j.humpath.2018.06.024_bb0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10689-007-9172-6","article-title":"Hereditary diffuse gastric cancer: association with lobular breast cancer","volume":"7","author":"Schrader","year":"2008","journal-title":"Fam Cancer"},{"key":"10.1016\/j.humpath.2018.06.024_bb0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/jmg.2007.051268","article-title":"Germline E-cadherin mutations in familial lobular breast cancer","volume":"44","author":"Masciari","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.humpath.2018.06.024_bb0055","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/bcr953","article-title":"Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families","volume":"7","author":"Eerola","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2018.06.024_bb0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000444326","article-title":"A Comparison between CHEK2*1100delC\/I157T mutation carrier and noncarrier breast cancer patients: a clinicopathological analysis","volume":"90","author":"Huszno","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.humpath.2018.06.024_bb0065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2559.2006.02538.x","article-title":"Histopathological features of breast cancer in carriers of ATM gene variants","volume":"49","author":"Balleine","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2018.06.024_bb0070","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2018.06.024_bb0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pathol.2017.03.002","article-title":"Non-BRCA familial breast cancer: review of reported pathology and molecular findings","volume":"49","author":"Keeney","year":"2017","journal-title":"Pathology"},{"key":"10.1016\/j.humpath.2018.06.024_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","article-title":"Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel","volume":"121","author":"Tung","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2018.06.024_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0546-7","article-title":"Lobular breast cancer: incidence and genetic and non-genetic risk factors","volume":"17","author":"Dossus","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2018.06.024_bb0090","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004614","article-title":"Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database","volume":"95","author":"Plasilova","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.humpath.2018.06.024_bb0095","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-013-2493-2","article-title":"Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast","volume":"138","author":"Arps","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2018.06.024_bb0100","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S1470-2045(06)70911-1","article-title":"Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis","volume":"7","author":"Reeves","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2018.06.024_bb0105","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jama.289.11.1421","article-title":"Trends in incidence rates of invasive lobular and ductal breast carcinoma","volume":"289","author":"Li","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.humpath.2018.06.024_bb0110","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y","article-title":"Somatic mutations and human breast cancer. A status report","volume":"69","author":"Callahan","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2018.06.024_bb0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1947601911413466","article-title":"Li-fraumeni syndrome","volume":"2","author":"Malkin","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.humpath.2018.06.024_bb0120","first-page":"83","article-title":"Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers","volume":"10","author":"Nichols","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.humpath.2018.06.024_bb0125","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jmg.2010.078113","article-title":"A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations","volume":"47","author":"Wilson","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.humpath.2018.06.024_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.ejhg.5201542","article-title":"BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition","volume":"14","author":"Vahteristo","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.humpath.2018.06.024_bb0135","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","article-title":"Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers","volume":"34","author":"Schmidt","year":"2016","journal-title":"J Clin Oncologia"},{"key":"10.1016\/j.humpath.2018.06.024_bb0140","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","article-title":"PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS","volume":"53","author":"Southey","year":"2016","journal-title":"J Med Genet"},{"key":"10.1016\/j.humpath.2018.06.024_bb0145","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/j.seminoncol.2016.10.001","article-title":"Updates on breast cancer genetics: clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer","volume":"43","author":"Cobain","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.humpath.2018.06.024_bb0150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.06.024_bb0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/bjc.2013.295","article-title":"Tumour morphology predicts PALB2 germline mutation status","volume":"109","author":"Teo","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2018.06.024_bb0160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene","volume":"39","author":"Rahman","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2018.06.024_bb0165","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/cncr.26506","article-title":"MutYH mutation carriers have increased breast cancer risk","volume":"118","author":"Rennert","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2018.06.024_bb0170","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/ijc.30197","article-title":"Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH","volume":"139","author":"Win","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2018.06.024_bb0175","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2559.2008.03071.x","article-title":"Pathological features of colorectal carcinomas in MYH-associated polyposis","volume":"53","author":"O'Shea","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2018.06.024_bb0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/bjs.9693","article-title":"Genotype-defined cancer risk in juvenile polyposis syndrome","volume":"102","author":"Aytac","year":"2015","journal-title":"Br J Surg"},{"key":"10.1016\/j.humpath.2018.06.024_bb0185","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jmg.2007.052506","article-title":"High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome","volume":"44","author":"Aretz","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.humpath.2018.06.024_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000452082","article-title":"Bloom's syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition","volume":"8","author":"Cunniff","year":"2017","journal-title":"Mol Syndromol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718302387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718302387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T10:32:58Z","timestamp":1545042778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817718302387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":38,"alternative-id":["S0046817718302387"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.06.024","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution\u2019s high-risk population","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}